Hims Hers Snaps Losing Streak as EPS Beat Fails Again
Hims & Hers beat quarterly EPS but trimmed full-year guidance, extending a slide in its stock as regulatory headwinds...
Discover practical ways to simplify expense tracking and minimize effort while staying accurate. A quick guide to streamlined budgeting.
10,960 articlesHims & Hers beat quarterly EPS but trimmed full-year guidance, extending a slide in its stock as regulatory headwinds...
Bridger Management quietly exited a large Bath & Body Works position in the fourth quarter, selling about 301,000 sha...
Meme coins can surprise with sudden moves, and Pepe is no exception. This article unpacks the drivers behind a sharp ...
TeraWulf releases Q4 2025 results after the bell, signaling a shift from Bitcoin mining to AI compute. After-hours tr...
Hims & Hers Health shares have been hammered, marked by a steep decline over past year. This article breaks down the ...
Cameco beat revenue and earnings targets, driven by ccj’s long term contract book that locks in cash flow through 202...
Trump’s historic line about abandoning nation-building now echoes into a markets-focused era. This piece explains wha...
Palantir trades near the $150 level amid volatility. This guide breaks down whether palantir technologies stock no-br...
OpenAI is renegotiating its Pentagon deal to block domestic surveillance, with new safeguards and agency restrictions...
A former lululemon executive voices governance concerns, highlighting how board independence, capital allocation, and...
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Solana’s SOL is hovering near a key $95 zone as traders watch for a breakout. Fresh data show rising volumes and a ti...